FTC effort to stop Amgen’s Horizon takeover faces uphill fight
By Diane Bartz WASHINGTON (Reuters) – The Federal Trade Commission (FTC) faces an uphill battle in its fight against Amgen Inc’s $27.8 billion acquisition of Horizon Therapeutics with an untested argument before a Trump-appointed judge, three antitrust experts said. Furthermore, the FTC’s complaint, unsealed late Tuesday, expresses concern about deals struck between drug companies that…
